Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • SMART2
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • SMART2
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

Use of Hepatitis C Virus (HCV) Immunoglobulin G Antibody Avidity as a Biomarker to Estimate the Population-Level Incidence of HCV Infection.
Patel EU, Cox AL, Mehta SH, Boon D, Mullis CE, Astemborski J, Osburn WO, Quinn J, Redd AD, Kirk GD, Thomas DL, Quinn TC, Laeyendecker O.
J Infect Dis, 2016: 214(3): 344-352, 10.1093/infdis/jiw005
Improvements in the continuum of HIV care in an inner-city emergency department.
Kelen GD, Hsieh YH, Rothman RE, Patel EU, Laeyendecker OB, Marzinke MA, Clarke W, Parsons T, Manucci JL, Quinn TC.
AIDS, 2016: 30(1): 113-120, 10.1097/QAD.0000000000000896
Antibody Maturation in Women Who Acquire HIV Infection While Using Antiretroviral Preexposure Prophylaxis.
Laeyendecker O, Redd AD, Nason M, Longosz AF, Karim QA, Naranbhai V, Garrett N, Eshleman SH, Abdool Karim SS, Quinn TC.
J Infect Dis, 2015: 212(5): 754-759, 10.1093/infdis/jiv110
Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.
Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O.
AIDS Res Hum Retroviruses, 2015: 31(4): 421-427, 10.1089/AID.2014.0081
Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction.
Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, Singer J, Pankovich J, Laeyendecker O, Kaul R, Kandel G, Kovacs C.
Open Forum Infect Dis, 2015: 2(4): ofv138, 10.1093/ofid/ofv138.
Short Communication: Low False Recent Rate of Limiting-Antigen Avidity Assay Among Long-Term Infected Subjects from Guangxi, China.
Yu L, Laeyendecker O, Wendel SK, Liang F, Liu W, Wang X, Wang L, Pang X, Fang Z.
AIDS Res Hum Retroviruses, 2015: 31(12): 1247-1249, 10.1089/aid.2015.0097
High HIV prevalence and incidence among MSM across 12 cities in India.
Solomon SS, Mehta SH, Srikrishnan AK, Vasudevan CK, Mcfall AM, Balakrishnan P, Anand S, Nandagopal P, Ogburn EL, Laeyendecker O, Lucas GM, Solomon S, Celentano DD.
AIDS, 2015: 29(6): 723-731, 10.1097/QAD.0000000000000602
High HIV burden among people who inject drugs in 15 Indian cities.
Lucas GM, Solomon SS, Srikrishnan AK, Agrawal A, Iqbal S, Laeyendecker O, McFall AM, Kumar MS, Ogburn EL, Celentano DD, Solomon S, Mehta SH.
AIDS, 2015: 29(5): 619-628, 10.1097/QAD.0000000000000592

Pages

  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Contact

Tel: 410-955-3551

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Justin Lessler
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6545
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2019 Infectious Disease Dynamics
Website by Manta Ray Media